Steven Heymsfield finds that a GLP-1 therapy combined with bimagrumab, an investigational agent that blocks activin signaling pathways, results in greater weight reduction than either drug alone A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue
Compounded Methylene Blue Enhance daily cognitive and cellular support Methylene Blue has gained attention in the wellness space for its potential role in supporting mitochondrial function, cognitive clarity, and cellular energy production
You may notice temporary flushing, headache, lightheadedness, nausea, or mild sleep disturbance
Ulcer Healing : Preclinical evidence shows accelerated healing of gastric ulcers through improved tissue regeneration
F50.0 Anorexia nervosa F50.2 Bulimia nervosa F50.8 Other eating disorders F50.9 Eating disorder, unspecified Accurate coding of eating disorders facilitates targeted therapeutic interventions and supports insurance reimbursement processes